Literature DB >> 17391613

Treatment of an infected total hip replacement with the PROSTALAC system. Part 2: Health-related quality of life and function with the PROSTALAC implant in situ.

Angela Scharfenberger1, Marcia Clark, Guy Lavoie, Greg O'Connor, Edward Masson, Lauren A Beaupre.   

Abstract

INTRODUCTION: Infection after total hip replacement (THR) adversely affects patients' function and health-related quality of life (HRQL). A prosthesis with antibiotic-loaded acrylic cement (PROSTALAC) was designed to improve the function and quality of life of patients undergoing treatment for infected THR.
METHODS: We assessed 23 patients with the PROSTALAC implant in situ for treatment of an infected THR for function and HRQL, using standardized outcome measures. These patients were compared with a referent cohort of patients who had undergone assessment of function and HRQL before and 6 months after primary THR in the same tertiary health centres.
RESULTS: The mean (standard deviation) Western Ontario MacMaster (WOMAC) scores for PROSTALAC patients were 70.0 (21.1), 65.8 (20.4) and 63.0 (21.1) for pain, stiffness and function, respectively. The median Harris Hip score was 62.3 (minimum 20.4, maximum 86.3) and median global hip range of motion was 100.0 (minimum 80.0, maximum 140.0) degrees.
CONCLUSION: The mean WOMAC scores for pain, stiffness and function were better than they were for patients awaiting THR but not as good as 6 months after primary THR. The PROSTALAC implant allows patients to have reasonable function and quality of life during the interim treatment for deep joint infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391613      PMCID: PMC2384256     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  16 in total

1.  Is the Harris hip score system useful to study the outcome of total hip replacement?

Authors:  P Söderman; H Malchau
Journal:  Clin Orthop Relat Res       Date:  2001-03       Impact factor: 4.176

2.  Temporary antibiotic loaded acrylic hip replacement: a novel method for management of the infected THA.

Authors:  R W Kendall; B A Masri; C P Duncan; C P Beauchamp; R W McGraw; B Bora
Journal:  Semin Arthroplasty       Date:  1994-10

3.  A cement spacer for two-stage revision of infected implants of the hip joint.

Authors:  M Leunig; E Chosa; M Speck; R Ganz
Journal:  Int Orthop       Date:  1998       Impact factor: 3.075

4.  Comparison of the WOMAC (Western Ontario and McMaster Universities) osteoarthritis index and a self-report format of the self-administered Lequesne-Algofunctional index in patients with knee and hip osteoarthritis.

Authors:  G Stucki; O Sangha; S Stucki; B A Michel; A Tyndall; W Dick; R Theiler
Journal:  Osteoarthritis Cartilage       Date:  1998-03       Impact factor: 6.576

5.  Treatment of infection associated with segmental bone loss in the proximal part of the femur in two stages with use of an antibiotic-loaded interval prosthesis.

Authors:  A S Younger; C P Duncan; B A Masri
Journal:  J Bone Joint Surg Am       Date:  1998-01       Impact factor: 5.284

6.  Health related quality of life outcomes after total hip and knee arthroplasties in a community based population.

Authors:  C A Jones; D C Voaklander; D W Johnston; M E Suarez-Almazor
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

7.  Measuring health status in older patients. The SF-36 in practice.

Authors:  S G Parker; S M Peet; C Jagger; M Farhan; C M Castleden
Journal:  Age Ageing       Date:  1998-01       Impact factor: 10.668

8.  Treatment of an infected total hip replacement with the PROSTALAC system. Part 1: Infection resolution.

Authors:  Angela Scharfenberger; Marcia Clark; Guy Lavoie; Greg O'Connor; Edward Masson; Lauren A Beaupre
Journal:  Can J Surg       Date:  2007-02       Impact factor: 2.089

9.  Comparison of a generic and a disease-specific measure of pain and physical function after knee replacement surgery.

Authors:  C Bombardier; C A Melfi; J Paul; R Green; G Hawker; J Wright; P Coyte
Journal:  Med Care       Date:  1995-04       Impact factor: 2.983

10.  The SF-36 health survey questionnaire: is it suitable for use with older adults?

Authors:  V Hayes; J Morris; C Wolfe; M Morgan
Journal:  Age Ageing       Date:  1995-03       Impact factor: 10.668

View more
  8 in total

1.  An articulating antibiotic spacer controls infection and improves pain and function in a degenerative septic hip.

Authors:  Erin E Fleck; Mark J Spangehl; Venkat R Rapuri; Christopher P Beauchamp
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

2.  The use of a preformed spacer in two-stage revision of infected hip arthroplasties.

Authors:  F D'Angelo; L Negri; T Binda; G Zatti; P Cherubino
Journal:  Musculoskelet Surg       Date:  2011-04-09

3.  Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis.

Authors:  Jeppe Lange; Anders Troelsen; Reimar W Thomsen; Kjeld Søballe
Journal:  Clin Epidemiol       Date:  2012-03-27       Impact factor: 4.790

4.  Revision of failed hip resurfacing to total hip arthroplasty rapidly relieves pain and improves function in the early post operative period.

Authors:  Nemandra A Sandiford; Sarah K Muirhead-Allwood; John A Skinner
Journal:  J Orthop Surg Res       Date:  2010-11-29       Impact factor: 2.359

5.  Application of temporarily functional antibiotic-containing bone cement prosthesis in revision hip arthroplasty.

Authors:  Ke Liu; Jia Zheng; Yi Jin; Yong-Qiang Zhao
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-11-23

Review 6.  Articular spacers in two-stage revision arthroplasty for prosthetic joint infection of the hip and the knee.

Authors:  Andy Craig; S W King; B H van Duren; V T Veysi; S Jain; J Palan
Journal:  EFORT Open Rev       Date:  2022-02-15

7.  One-stage or two-stage revision surgery for prosthetic hip joint infection--the INFORM trial: a study protocol for a randomised controlled trial.

Authors:  Simon Strange; Michael R Whitehouse; Andrew D Beswick; Tim Board; Amanda Burston; Ben Burston; Fran E Carroll; Paul Dieppe; Kirsty Garfield; Rachael Gooberman-Hill; Stephen Jones; Setor Kunutsor; Athene Lane; Erik Lenguerrand; Alasdair MacGowan; Andrew Moore; Sian Noble; Joanne Simon; Ian Stockley; Adrian H Taylor; Andrew Toms; Jason Webb; John-Paul Whittaker; Matthew Wilson; Vikki Wylde; Ashley W Blom
Journal:  Trials       Date:  2016-02-17       Impact factor: 2.279

8.  Results and Patient Reported Outcome Measures (PROMs) after One-Stage Revision for Periprosthetic Joint Infection of the Hip: A Single-centre Retrospective Study.

Authors:  Jesse W P Kuiper; Christine M E Rustenburg; Jore H Willems; Steven J Verberne; Edgar J G Peters; Rachid Saouti
Journal:  J Bone Jt Infect       Date:  2018-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.